OTC:CC - Ocumetics Announces Commencement of Biocompatibility and Animal Studies for Updated Lens Design
(TheNewswire)
Calgary, Alberta – TheNewswire - June 20 , 2023 - Ocumetics Technology Corp. (TSXV:OTC)(OTC:OTCFF) (FRA:2QBO) (“ Ocumetics ” or the “ Company ”) is pleased to announce that the Company has reached amajor milestone with the start of biocompatibility and animal studiesfor its updated lens design.
As a result of extensive product testing andpreliminary animal studies over the past 18 months, the Ocumeticsresearch and development team made several design enhancements to theOcumetics accommodating lens. On April 19, 2023, the Company announcedproduct design lockdown.
“Our latest lens design update addressed animplantation challenge identified from our first animal study andfeedback received from our Medical Advisory Board at the 2023 ASCRSmeeting,” said Dean Burns, Ocumetics’ President and CEO.
“These new studies are to ensure that the lens designhas a safe biological response when implanted within the eye and it isa significant milestone towards meeting FDA regulatory safetyrequirements ,” said Dr. Barbara Fant,President of Clinical Research Consultants, Ocumetics’ regulatoryconsultant.
“It is exciting to see the technology we havedeveloped coming to fruition,” added Ocumetics’ Chief MedicalOfficer, Dr. Doyle Stulting.
The biocompatibility studies will take 4-5 months tocomplete. Ocumetics expects to begin planning its first-in-humanproof of concept studies by Q4 2023.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO) is a Canadian research and development company thatspecializes in adaptive intraocular lens designs. Ocumetics is in thepreclinical study stage of a game-changing technology for theophthalmic industry. Ocumetics has developed an expandableintraocular lens that fits within the capsular bag followingextracapsular cataract extraction. It is designed to allow the eyesnatural muscle activity to shift focus from distance to near,potentially to eliminate the need for corrective lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dean Burns, President and CEO
(817) 874-7564
Dayton Marks, Director
(778) 347-2500
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
Copyright (c) 2023 TheNewswire - All rights reserved.